The long-term goal of establishing the clinical use of exosomes in diagnostics and therapeutics is to reduce unnecessary biopsies, overdiagnosis, and overtreatment of prostate cancer, while increasing the ability to detect high-risk cancers that may have been missed with a PSA test. This evidence concerns the gene KLK3 and Familial prostate cancer.